$PRVB Weekend Summary. Rarely do we have as exciting a weekend as we have had this weekend. Here is a quick summary. Biotech stock picking expert, Nick Dihn @nickpd, released an extensive research report on Provention's lead drug, Teplizumab. He believes the FDA clearly wants to bring this important biologic drug to the market for the pediatric population. writer.zohopublic.com/write... Short interest climbed 35% to 1.9m The company updated their investor presentation before the JP Morgan Healthcare conference. This presentation indicated the target market for their T1D drug, Teplizumab, is actually at least 3 times larger than originally thought. New report joesstockreports.wordpress.... Updated report with a revised target of $200/share joesstockreports.wordpress....
  • 17
  • 1